INDIANAPOLIS, IN
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)HOOSIER CANCER RESEARCH NETWORK INC, founded in 2007, is a mid-sized nonprofit in the Health Care sector that reported $15.8M in total revenue in fiscal year 2024. Revenue grew 13% year-over-year, indicating healthy expansion. Expenses of $15.3M left a modest 3% surplus.
TO FORM UNPARALLELED RELATIONSHIPS BETWEEN ACADEMIC, COMMUNITY, PHARMACEUTICAL, AND BIOTECH COLLABORATORS WITH THE GOAL OF ADVANCING CANCER RESEARCH, EDUCATION, AND PATIENT ADVOCACY.
INVESTIGATOR-INITIATED STUDIES - THESE ARE STUDIES CREATED BY NON-INDUSTRY PHYSICIANS, MOST COMMONLY FOR US FROM ACADEMIC INSTITUTIONS BUT POSSIBLY ALSO FROM COMMUNITY SITES, AND THOSE PHYSICIANS...
INVESTIGATOR-INITIATED STUDIES - THESE ARE STUDIES CREATED BY NON-INDUSTRY PHYSICIANS, MOST COMMONLY FOR US FROM ACADEMIC INSTITUTIONS BUT POSSIBLY ALSO FROM COMMUNITY SITES, AND THOSE PHYSICIANS SERVE AS SPONSOR-INVESTIGATORS. WHEN WE CONDUCT/MANAGE THESE STUDIES, WE PRESERVE RIGHTS FOR US AND OUR MEMBER INSTITUTIONS TO PUBLISH AND ACCESS DATA FOR THE PUBLIC BENEFIT CONSISTENT WITH OUR TAX EXEMPT PURPOSE. THESE STUDIES MAY BE FUNDED BY INDUSTRY, BUT INDUSTRY IS NOT THE SPONSOR. THESE STUDIES MAY ALSO BE FUNDED BY PHILANTHROPIC ORGANIZATIONS, AND IN SOME CASES PUBLIC AND PRIVATE UNIVERSITIES. THE SPONSOR INVESTIGATOR OWNS THE PROTOCOL AND DATA IN AN IIT AND INDUSTRY GETS TO USE THE DATA.
INDUSTRY-SPONSORED STUDIES - ON RARE OCCASIONS, WE GET INVOLVED IN INDUSTRY-SPONSORED STUDIES, MEANING A STUDY INITIATED AND CONDUCTED BY A PHARMACEUTICAL COMPANY. WHEN WE WORK ON THOSE STUDIES, WE...
INDUSTRY-SPONSORED STUDIES - ON RARE OCCASIONS, WE GET INVOLVED IN INDUSTRY-SPONSORED STUDIES, MEANING A STUDY INITIATED AND CONDUCTED BY A PHARMACEUTICAL COMPANY. WHEN WE WORK ON THOSE STUDIES, WE PRESERVE RIGHTS FOR US AND OUR SITES TO PUBLISH AND ACCESS DATA FOR THE PUBLICBENEFIT CONSISTENT WITH OUR TAX-EXEMPT PURPOSE. PHARMA FUNDS THESE STUDIES AND ALSO ACTS AS THE SPONSOR. PHARMA OWNS THE PROTOCOL AND DATA IN THESE STUDIES, AND SITES (AND WE) GET TO USE THE DATA FOR PUBLICATION PURPOSES.
BTCRC ADMINISTRATION - HCRN IS THE ADMINISTRATIVE HEADQUARTERS OF THE BIG TEN CANCER REASEARCH CONSORTIUM (BTCRC). EACH MEMBER INSTITUTION PAYS IN DUES WHICH SUPPORT CONSORTIUM OPERATIONS INCLUDING...
BTCRC ADMINISTRATION - HCRN IS THE ADMINISTRATIVE HEADQUARTERS OF THE BIG TEN CANCER REASEARCH CONSORTIUM (BTCRC). EACH MEMBER INSTITUTION PAYS IN DUES WHICH SUPPORT CONSORTIUM OPERATIONS INCLUDING THE BTCRC CHIEF SCIENTIFIC OFFICER, WORKING GROUP COORDINATION, LOI DEVELOPMENT, EVENT MANAGEMENT, AND OVERHEAD. THE BTCRC IS LED BY A STEERING COMMITTEE COMPOSED OF ONE RESEARCHER FROM EACH MEMBER INSTITUTION.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $15,763,357 | $13,897,446 | +0.1% |
| Expenses | $15,276,668 | $14,211,759 | +0.1% |
| Net Income | $486,689 | $-314,313 | -2.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| PATRICK LOEHRER MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $248,881 |
| CHRIS WAYNE | TREASURER | 0.50 |
Officer
Director
|
$0 | $0 | $119,788 |
| BROOKE PATZ | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $118,932 |
| RITA ASSI MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $52,360 |
| JENNIFER KING MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $52,030 |
| TIM LAUTENSCHLAEGER MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $41,274 |
| CHRIS FAUSEL PHARMD | CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ANNETTE MOORE MD | SECRETARY | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| CHRIS LEMASTERS | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $0 |
| ANDREW MESECAR PHD | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $0 |
| BRIAN STEMME | CEO | 40.00 |
Officer
|
$315,884 | $53,875 | $369,759 |
| MARK INGOLD | CFO | 40.00 |
Officer
|
$174,284 | $26,395 | $200,679 |
| JEFF SMITH | COO | 40.00 |
Officer
|
$148,749 | $17,999 | $166,748 |
| KAREN DUTCHER | GENERAL COUNSEL | 40.00 |
Highest
|
$149,804 | $32,483 | $182,287 |
| LEAETTA HYER | RESEARCH DEVELOPMENT OFFICER | 40.00 |
Highest
|
$136,862 | $39,467 | $176,329 |
| CHRISTY YODER | SAFETY AND REGULATORY OFFICER | 40.00 |
Highest
|
$122,451 | $23,544 | $145,995 |
| ANITA CAMIC | CONTRACTS AND QUALITY ASSURANCE OFFICER | 40.00 |
Highest
|
$115,068 | $15,575 | $130,643 |
| LISA WOOD | RESEARCH DEVELOPMENT DIRECTOR | 40.00 |
Highest
|
$113,260 | $17,358 | $130,618 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $15,763,357 | $15,276,668 | $14,903,245 | $486,689 |
| 2024 | $13,897,446 | $14,211,759 | $14,561,673 | $-314,313 |
| 2023 | $14,101,658 | $12,030,652 | $13,703,057 | $2,071,006 |
| 2022 | $10,310,704 | $11,389,130 | $10,358,529 | $-1,078,426 |
| 2021 | $12,660,733 | $12,750,933 | $13,291,653 | $-90,200 |
| 2020 | $15,860,062 | $15,077,905 | $13,457,963 | $782,157 |
| 2019 | $15,096,493 | $12,441,245 | $10,754,421 | $2,655,248 |
| 2018 | $11,604,278 | $9,914,693 | $7,694,149 | $1,689,585 |
Compare HOOSIER CANCER RESEARCH NETWORK INC with other nonprofits in Indiana and across the country.